KC

KELLY CHILDRESS LANGE

EAST END GROUP, LLC · Chevy Chase, MD · registered since 2024
Registered · LDAActive

At a glance

Registered since
2024
Senate LDA system
Clients
7
last 3 years
Filings
15
3 agencies contacted
Activity
filings by quarter
Works on

Background

Government experience
Rep. Shimkus
LA; Rep. Rogers, Health Policy Director
Disclosed on LD-2 filings
Rep. Shimkus
LA, Rep. Rogers, LA, Health Policy Advisor
Disclosed on LD-2 filings
Rep. Shimkus
LA; Rep. Rogers, Health Policy Adviser.
Disclosed on LD-2 filings
Rep. Shimkus
LA; Rep. Mike Rogers, LA
Disclosed on LD-2 filings
Rep. Mike Rogers
LA; Rep. John Shimkus, LA.
Disclosed on LD-2 filings
Career
Chevy Chase, MD
2024 - present

Specific issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for the Public Health Social Services Emergency Fund (PHSSEF)- Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield; Education and awareness related to therapeutics for prevention or treatment of serious viral diseases.
Health Issues · 2024 Q2
Reauthorization of the Pandemic and All-Hazards Preparedness Act, legislative and regulatory issues related to vaccine and diagnostic research, development and stockpiling. LHHS preparedness appropriations.
Health Issues · 2024 Q2
Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals, and the reauthorization of the Pandemic and All-Hazards Preparedness Act.
Health Issues · 2024 Q2
Legislatives issues related to pandemic preparedness and response, and the reauthorization of the Pandemic and All-Hazards Preparedness Act. Funding for pandemic influenza in the LHHS Appropriations bill.
Health Issues · 2024 Q2
Legislatives issues related to biodefense preparedness and response, and the reauthorization of the Pandemic and All-Hazards Preparedness Act. Funding for the Biomedical Advanced Research and Development Authority in the LHHS Appropriations bill.
Health Issues · 2024 Q2
General health care coverage and reimbursement for prescription drugs; drug pricing reform and related issues; and the Food and Drug Administration legislative and regulatory issues.
Health Issues · 2024 Q2

Clients

2024 · 3 filings
$██,███ / qtrUnlock
2024 · 2 filings
$██,███ / qtrUnlock
2024 · 2 filings
$██,███ / qtrUnlock
2024 · 2 filings
$██,███ / qtrUnlock
2024 · 2 filings
$██,███ / qtrUnlock
$██,███ / qtrUnlock
2024 · 2 filings
$██,███ / qtrUnlock

Filing history

2024 Q2
GLAXOSMITHKLINE
Q2lda.gov →
2024 Q2
SEQIRUS
Q2lda.gov →
2024 Q2
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Q2lda.gov →
2024 Q2
INVIVYD, INC.
Q2lda.gov →
2024 Q2
LONGHORN
Q2lda.gov →
2024 Q2
ALVOGEN
Q2lda.gov →
2024 Q2
BAVARIAN NORDIC INC.
Q2lda.gov →
2024 Q1
INVIVYD, INC.
RRlda.gov →
2024 Q1
GLAXOSMITHKLINE
Q1lda.gov →
2024 Q1
SEQIRUS
Q1lda.gov →
2024 Q1
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Q1lda.gov →
2024 Q1
INVIVYD, INC.
Q1lda.gov →
Showing recent filings · full history on lda.gov